137 related articles for article (PubMed ID: 36803869)
21. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237
[TBL] [Abstract][Full Text] [Related]
22. [Circulating vaccine-derived poliovirus type 2 outbreak in Democratic Republic of Congo 2011-2012].
Bazira L; Coulibaly T; Mayenga M; Ncharre C; Yogolelo R; Mbule A; Moudzeo H; Lwamba P; Mulumba AW; Cabore J
Bull Soc Pathol Exot; 2015 Oct; 108(4):235-41. PubMed ID: 26288132
[TBL] [Abstract][Full Text] [Related]
23. Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned.
Afsar A; Mallya A; Mohammed AAG; Anand S; Diomande VKF; Maufras du Châtellier G; Ather F
Vaccine; 2023 Apr; 41 Suppl 1():A79-A84. PubMed ID: 36642630
[TBL] [Abstract][Full Text] [Related]
24. Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria.
Voorman A; Lyons H; Shuaib F; Adamu US; Korir C; Erbeto T; Bandyopadhyay AS; Okiror S
J Infect Dis; 2024 Mar; 229(3):805-812. PubMed ID: 37357964
[TBL] [Abstract][Full Text] [Related]
25. Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017.
Jorba J; Diop OM; Iber J; Henderson E; Sutter RW; Wassilak SGF; Burns CC
MMWR Morb Mortal Wkly Rep; 2017 Nov; 66(43):1185-1191. PubMed ID: 29095803
[TBL] [Abstract][Full Text] [Related]
26. Updated Characterization of Poliovirus Transmission in Pakistan and Afghanistan and the Impacts of Different Outbreak Response Vaccine Options.
Kalkowska DA; Pallansch MA; Cochi SL; Thompson KM
J Infect Dis; 2021 Nov; 224(9):1529-1538. PubMed ID: 33885734
[TBL] [Abstract][Full Text] [Related]
27. Environmental Isolation of Circulating Vaccine-Derived Poliovirus After Interruption of Wild Poliovirus Transmission - Nigeria, 2016.
Etsano A; Damisa E; Shuaib F; Nganda GW; Enemaku O; Usman S; Adeniji A; Jorba J; Iber J; Ohuabunwo C; Nnadi C; Wiesen E
MMWR Morb Mortal Wkly Rep; 2016 Aug; 65(30):770-3. PubMed ID: 27490081
[TBL] [Abstract][Full Text] [Related]
28. Detection of vaccine-derived poliovirus circulation by environmental surveillance in the absence of clinical cases.
Odoom JK; Obodai E; Boateng G; Diamenu S; Attiku K; Avevor P; Duker E; Boahene B; Eshun M; Gberbie E; Opare JKL
Hum Vaccin Immunother; 2021 Jul; 17(7):2117-2124. PubMed ID: 33517832
[TBL] [Abstract][Full Text] [Related]
29. Outbreak response strategies with type 2-containing oral poliovirus vaccines.
Kalkowska DA; Wassilak SGF; Pallansch MA; Burns CC; Wiesen E; Durry E; Badizadegan K; Thompson KM
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A142-A152. PubMed ID: 36402659
[TBL] [Abstract][Full Text] [Related]
30. An epidemiological analysis of Acute Flaccid Paralysis (AFP)Â surveillance in Kenya, 2016 to 2018.
Tesfaye B; Sowe A; Kisangau N; Ogange J; Ntoburi S; Nekar I; Muitherero C; Camara Y; Gathenji C; Langat D; Sergon K; Limo H; Nzunza R; Kiptoon S; Kareko D; Onuekwusi I
BMC Infect Dis; 2020 Aug; 20(1):611. PubMed ID: 32811467
[TBL] [Abstract][Full Text] [Related]
31. The risk of type 2 oral polio vaccine use in post-cessation outbreak response.
McCarthy KA; Chabot-Couture G; Famulare M; Lyons HM; Mercer LD
BMC Med; 2017 Oct; 15(1):175. PubMed ID: 28974220
[TBL] [Abstract][Full Text] [Related]
32. The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.
Burkholder B; Wadood Z; Kassem AM; Ehrhardt D; Zomahoun D
Vaccine; 2023 Apr; 41 Suppl 1():A2-A11. PubMed ID: 34756614
[TBL] [Abstract][Full Text] [Related]
33. Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates.
Kroiss SJ; Famulare M; Lyons H; McCarthy KA; Mercer LD; Chabot-Couture G
Vaccine; 2017 Oct; 35(42):5674-5681. PubMed ID: 28890193
[TBL] [Abstract][Full Text] [Related]
34. Curbing an outbreak of circulating vaccine derived poliovirus type 2 in Dollo Zone, Somali Region, Ethiopia: response to outbreak.
Kidanne L; Bisrat F; Mohammed M; Deyessa N
Pan Afr Med J; 2022; 42():46. PubMed ID: 35949467
[TBL] [Abstract][Full Text] [Related]
35. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2018-June 2019.
Jorba J; Diop OM; Iber J; Henderson E; Zhao K; Quddus A; Sutter R; Vertefeuille JF; Wenger J; Wassilak SGF; Pallansch MA; Burns CC
MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(45):1024-1028. PubMed ID: 31725706
[TBL] [Abstract][Full Text] [Related]
36. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
[TBL] [Abstract][Full Text] [Related]
37. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
Voorman A; Lyons H; Bennette C; Kovacs S; Makam JK; F Vertefeuille J; Tallis G
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A85-A92. PubMed ID: 35339308
[TBL] [Abstract][Full Text] [Related]
38. Notes from the Field: Circulating Vaccine-Derived Poliovirus Outbreaks - Five Countries, 2014-2015.
Morales M; Nnadi CD; Tangermann RH; Wassilak SG
MMWR Morb Mortal Wkly Rep; 2016 Feb; 65(5):128-9. PubMed ID: 26866942
[TBL] [Abstract][Full Text] [Related]
39. Effective partnership and in-country resource mobilization in Sudan for cVDPV2 outbreak response amid multiple emergencies in 2020-2021.
Mashal MT; Eltayeb D; Higgins-Steele A; El Sheikh IS; Abid NS; Shukla H; Machado L; Jafari H
BMC Public Health; 2024 Jan; 24(1):235. PubMed ID: 38243167
[TBL] [Abstract][Full Text] [Related]
40. Progress Toward Poliomyelitis Eradication - Pakistan, January 2021-July 2022.
Mbaeyi C; Baig S; Safdar MR; Khan Z; Young H; Jorba J; Wadood ZM; Jafari H; Alam MM; Franka R
MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1313-1318. PubMed ID: 36264783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
